· Singmed self-developed product

· Multi-dose Blister DPI

· The self-developed Ellipta® innovated by Singmed has been conducting Bioequivalence researching with a number of Chinese leading listed pharmaceutical companies.

· With a distinctive product appearance, the atomization performance and the aerodynamic basis of our device are proved to be equivalent to the novel product, allowing for replacement of the novel device (Anoro® Ellipta® produced by GSK). We are capable of providing customers with integrated customized services encompassing research and development, design, and production.

· Inspiratory resistance range 0.04 to 0.06（kPa·s/L）